? The objective of the Hawaii Minority-Based Community Clinical Oncology Program (MBCCOP) is to build on its past 10 years' success in providing NCI clinical trials to Hawaii cancer patients and high risk individuals in order to reduce cancer incidence, morbidity and mortality by: ? 1. Providing support to expand clinical research in the state of Hawaii, a multi-ethnic ? population with a majority of ethnic minority cancer patients; ? 2. Bringing the advantages of state-of-the-science treatment and cancer prevention and ? control research to minority individuals in their own communities; ? 3. Increasing the involvement of primary health care providers and other specialists in ? cancer treatment, prevention and control studies; ? 4. Facilitating wider participation among underserved populations in NCI-approved research; ? 5. Strengthening the operational base that currently exists to extend cancer prevention and control research in this population. ? ? The Cancer Research Center of Hawaii will serve as the administrative headquarters for the MBCCOP to direct recruitment, accrual, and data management for NCI-approved cancer treatment, prevention and symptom control clinical trials. Sources of clinical trials include: SWOG, NCCTG, COG, GOG, RTOG, URCC, NSABP prevention trials, and CTSU. Participating physicians include all oncologists on the island of Oahu, as well as professionals from other medical and non-medical specialties. All major Oahu hospitals will serve as component institutions. The MBCCOP will allow the people of Hawaii, about 75 percent who are ethnic minorities, to benefit from access to state-of-the science cancer treatment, prevention and symptom control interventions, and to provide clinical research data on a unique population. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA063844-15
Application #
7465633
Study Section
Special Emphasis Panel (ZCA1-SRRB-D (J1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
1994-08-01
Project End
2010-05-31
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
15
Fiscal Year
2008
Total Cost
$778,279
Indirect Cost
Name
University of Hawaii
Department
Type
Organized Research Units
DUNS #
965088057
City
Honolulu
State
HI
Country
United States
Zip Code
96822
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Malhotra, Binu; Moon, James; Kucuk, Omar et al. (2014) Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329. Head Neck 36:1712-7

Showing the most recent 10 out of 115 publications